Spots Global Cancer Trial Database for Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases

Official Title: A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer

Study ID: NCT02187822

Conditions

Brain Metastases

Generalized Malignancy, Primary

Brain Lesions

Interventions

TPI 287

Fractionated Stereotactic Radiotherapy (FSRT)

Study Description

Brief Summary: The main purpose of this study is to see whether addition of TPI 287 to FSRT is safe and tolerable. Researchers also want to find out if adding TPI 287 to FSRT can help with better controlling the growth of brain lesions in people with brain metastases from their cancer.

Detailed Description: Standard of care for treatment of patients with brain metastases, which are considered not surgically removable, is radiation therapy to the brain lesions. This treatment is called Fractionated Stereotactic Radiotherapy (FSRT) and is given without chemotherapy and usually over 5 days. Researchers of this study want to find out if adding an investigational drug, called TPI 287, to standard radiation therapy (FSRT) can help people with brain metastases from cancer. TPI 287 is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).